	PMID	PT	OT	MH	SI	TI	GR
23	33317461	Journal Article;Randomized Controlled Trial	O  NNLM;Arbidol;COVID19;Corona virus;Efficacy	Adult;Aged;Antiviral Agents/*therapeutic use;COVID19/*drug therapy;Drug Combinations;Female;Humans;Hydroxychloroquine/therapeutic use;Indoles/*therapeutic use;Lopinavir/therapeutic use;Male;Middle Aged;Pandemics;Ritonavir/therapeutic use;SARSCoV2;DA 2020/12/19 06:00		Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial.	17640/Iran University of Medical Sciences/
42	33397429	Clinical Trial Protocol;Letter	O  NNLM;COVID19;Clinical symptoms;Hospitalization Mechanical ventilation;Ivermectin;Protocol;Randomized controlled trial	Administration, Oral;Adult;Antiviral Agents/*administration & dosage/adverse effects;COVID19/diagnosis/*drug therapy/virology;Clinical Trials, Phase III as Topic;Drug Therapy, Combination/adverse effects/methods;Female;Humans;Hydroxychloroquine/administration & dosage/adverse effects;Intensive Care Units/statistics & numerical data;Interferon beta1a/administration & dosage/adverse effects;Iran;Ivermectin/*administration & dosage/adverse effects;Length of Stay/statistics & numerical data;Lopinavir/administration & dosage/adverse effects;Male;Randomized Controlled Trials as Topic;Ritonavir/administration & dosage/adverse effects;SARSCoV2/drug effects/*isolation & purification;Severity of Illness Index;DA 2021/01/13 06:00		The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A 	990238/Hormozgan University of Medical Sciences/
89	33264337	Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Adult;COVID19/*drug therapy;Female;Humans;Hydroxychloroquine/*adverse effects/*therapeutic use;Male;Middle Aged;Retrospective Studies;*Safety;Standard of Care;Treatment Outcome;Young Adult;DA 2020/12/15 06:00		A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and 	
100	33234158	Letter;Randomized Controlled Trial	O  NNLM;COVID19;Hospitalization;Ivermectin;Protocol;Randomized controlled trial	Adult;Antiparasitic Agents/administration & dosage/*therapeutic use;Argentina/epidemiology;COVID19/*drug therapy/epidemiology/virology;CaseControl Studies;DoubleBlind Method;Female;Hospitalization/statistics & numerical data;Humans;Ivermectin/administration & dosage/*therapeutic use;Male;Pandemics/prevention & control;Placebos/administration & dosage;Prospective Studies;SARSCoV2/*genetics;Time Factors;DA 2020/12/15 06:00	ClinicalTrials.gov/NCT04529525	Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): 	
